Focus: Airiver Medical is a 5,000+ employee biotechnology company headquartered in Brooklyn Park, Minnesota, specializing in drug-coated balloon technology for respiratory infections.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
No open roles listed right now. Follow Airiver Medical to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Airiver Medical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Airiver Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moRecent peer-reviewed publications with author affiliations at this company
All Roads Can Lead to Stent Expansion if Guided by the Map of Intravascular Imaging.
Impact of Restenosis Pattern on the Safety and Efficacy of Paclitaxel-Coated Balloon Versus Uncoated Balloon for Coronary In-Stent Restenosis.
Outcomes of Patients With New Left Bundle Branch Block After TAVR: TVT Registry Insights.
Rethinking CTO PCI as a 2-Stage Procedure to Maximize Efficacy, and Hopefully Safety: The STAR Trial.
Paclitaxel-Coated Balloon for Treating In-Stent Restenosis in Racial and Ethnic Minority Patients: A Subanalysis From the AGENT IDE Trial.
Showing 5 of 10 publications